Loading...
India's cyclophosphamide imports from CANADA total $11.9K across 5 shipments from 4 foreign suppliers. ESPEE PHARMA CANADA INC. leads with $4.8K in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include DR.REDDY'S LABORATORIES LTD. This corridor reflects India's pharmaceutical import demand for cyclophosphamide — a diversified sourcing base with multiple active suppliers from CANADA.
ESPEE PHARMA CANADA INC. is the leading Cyclophosphamide supplier from CANADA to India, with import value of $4.8K across 2 shipments. The top 5 suppliers — ESPEE PHARMA CANADA INC., ADIRAMEDICA INC, RX SOURCE CORP., XXRCAXXPHAXXACEXXICAXX INX — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | ESPEE PHARMA CANADA INC. | $4.8K | 2 | 40.6% |
| 2 | ADIRAMEDICA INC | $4.0K | 1 | 33.6% |
| 3 | RX SOURCE CORP. | $2.9K | 1 | 24.4% |
| 4 | XXRCAXXPHAXXACEXXICAXX INX | $168 | 1 | 1.4% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | DR.REDDY'S LABORATORIES LTD | $11.7K | 4 | 98.6% |
| 2 | SHILPA MEDICARE LIMITED | $168 | 1 | 1.4% |
CANADA → India trade corridor intelligence
The Canada to India trade corridor for pharmaceutical imports, including Cyclophosphamide formulations, is characterized by:
1. Port Congestion: Major Indian ports such as Jawaharlal Nehru Port (JNPT), Chennai, and Mundra have experienced congestion, potentially affecting the timely clearance of pharmaceutical imports.
2. Freight Rates: Freight rates for shipments from Canada to India have seen fluctuations due to global supply chain dynamics and fuel price variations.
3. Currency Exchange: The exchange rate between the Canadian Dollar (CAD) and the Indian Rupee (INR) influences the landed cost of imports, with recent trends showing a strengthening of the CAD against the INR.
Importers should monitor these factors to optimize their supply chain operations.
India's Pharmaceutical Industry (PLI) scheme and self-reliance initiatives impact the import of finished pharmaceutical formulations, including Cyclophosphamide:
1. PLI Scheme Impact: The PLI scheme aims to boost domestic manufacturing, potentially reducing reliance on imports by incentivizing local production of pharmaceutical products.
2. Import Substitution Policies: Policies encouraging the development of domestic alternatives to imported drugs may affect the demand for imported Cyclophosphamide formulations.
3. Reducing Import Dependency: Efforts to enhance domestic production capabilities are underway to decrease dependency on foreign suppliers for critical medications.
These initiatives may influence the volume and nature of Cyclophosphamide imports from Canada to India.
The trade relationship between India and Canada, particularly
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Cyclophosphamide (HS Code 30049041) into India, the following regulatory steps are mandatory:
1. Import Registration and License: Obtain an import license from the Central Drugs Standard Control Organization (CDSCO) as per the Drugs and Cosmetics Act, 1940, and associated rules. This license is essential for the legal import and sale of pharmaceutical products in India.
2. CDSCO Registration: Ensure that the product is registered with CDSCO. This involves submitting detailed information about the product, including its composition, manufacturing process, and labeling.
3. Form CT-20/40/41: Depending on the nature of the product, specific forms such as CT-20 (for new drugs), CT-40 (for clinical trials), or CT-41 (for import of drugs) may be required.
4. DCGI Approval: The Drug Controller General of India (DCGI) must approve the product, confirming its safety, efficacy, and quality.
5. No Objection Certificate (NOC): If the product is manufactured in a Special Economic Zone (SEZ) and intended for sale in the Domestic Tariff Area (DTA), an NOC from the SEZ authority is required.
6. Timeline for Import Drug Registration: The registration process can take several months, depending on the completeness of the application and the regulatory workload.
For Cyclophosphamide formulations under HS Code 30049041, ensure compliance with all CDSCO requirements to facilitate smooth importation.
Imported finished pharmaceutical formulations containing Cyclophosphamide (HS Code 30049041) must undergo stringent quality control measures:
1. CDSCO-Approved Laboratory Testing: Samples from each batch must be tested in laboratories approved by CDSCO to verify compliance with Indian Pharmacopoeia standards.
2. Batch-Wise Requirements: Each batch of the imported product must be accompanied by a Certificate of Analysis (CoA) issued by the manufacturer, detailing the product's composition, purity, and other quality parameters.
3. Stability Data: Provide stability data demonstrating the product's shelf-life under Indian climatic conditions, adhering to ICH Zone IV guidelines.
4. Port Inspection: Upon arrival, customs drug inspectors may conduct inspections to ensure compliance with regulatory standards.
Adhering to these requirements ensures that imported Cyclophosphamide formulations meet India's quality and safety standards.
Between 2024 and 2026, India has implemented several regulatory updates affecting the import of finished pharmaceutical formulations containing Cyclophosphamide (HS Code 30049041):
1. Mandatory Import Registration and License: As of April 2025, CDSCO has mandated that all imported medicines, including Cyclophosphamide formulations, must obtain import registration and licenses to prevent the sale of unapproved or illegal medicines in the Indian market.
2. Quality Control Enhancements: The introduction of stricter quality control measures, including mandatory testing in CDSCO-approved laboratories and submission of stability data, aims to ensure the safety and efficacy of imported pharmaceutical products.
3. Regulatory Streamlining: Efforts to streamline the import process have been undertaken to facilitate smoother entry of pharmaceutical products into the Indian market, reducing bureaucratic delays.
These policy changes reflect India's commitment to enhancing the quality and safety of imported pharmaceutical formulations.
Market demand, customs duty structure, and competitive landscape · Import duty: 10%
India imports finished pharmaceutical formulations containing Cyclophosphamide due to several factors:
1. Patented and Branded Formulations: Certain patented or branded Cyclophosphamide formulations not manufactured domestically are sourced from international markets to meet patient needs.
2. Specific Dosage Forms: Specialized dosage forms, such as injectable Cyclophosphamide, may not be produced locally, necessitating imports to provide comprehensive treatment options.
3. Domestic Capacity vs. Import Dependency: While India has a robust pharmaceutical manufacturing sector, the demand for Cyclophosphamide formulations sometimes exceeds domestic production capacity, leading to reliance on imports.
4. Market Size: The Indian market for Cyclophosphamide formulations is substantial, driven by the prevalence of cancers and other conditions treated with this drug.
These factors contribute to the sustained demand for imported Cyclophosphamide formulations in India.
The import of finished pharmaceutical formulations containing Cyclophosphamide (HS Code 30049041) into India is subject to the following customs duties:
1. Basic Customs Duty (BCD): The standard BCD for this product is 10%.
2. Social Welfare Surcharge (SWS): An additional 10% of the BCD, amounting to 1%, is levied as SWS.
3. Integrated Goods and Services Tax (IGST): IGST is applicable at a rate of 18% on the total of BCD and SWS.
4. Anti-Dumping Duty: Currently, there are no anti-dumping duties imposed on Cyclophosphamide formulations under HS Code 30049041.
5. Exemption Notifications: There are no specific exemption notifications for this product.
6. Total Landed Duty: The cumulative duty, including BCD, SWS, and IGST, results in a total landed duty of approximately 29%.
Importers should account for these duties when calculating the total cost of importing Cyclophosphamide formulations into India.
India sources finished pharmaceutical formulations containing Cyclophosphamide from Canada due to several competitive advantages:
1. Patents and Specialized Dosage Forms: Canadian manufacturers may offer patented formulations or specialized dosage forms of Cyclophosphamide not available from other suppliers.
2. Quality Assurance: Canada's stringent regulatory standards ensure high-quality pharmaceutical products, making them attractive to Indian importers seeking reliable sources.
3. Regulatory Compliance: Canadian pharmaceutical products are often compliant with international standards, facilitating smoother import processes into India.
Other suppliers, such as China, Germany, and the United States, also provide Cyclophosphamide formulations to India. However, Canada's offerings may be preferred due to the factors mentioned above.
Canada's share in India's Cyclophosphamide import market is significant, reflecting its competitive position.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Cyclophosphamide suppliers from CANADA to India include ESPEE PHARMA CANADA INC., ADIRAMEDICA INC, RX SOURCE CORP.. The leading supplier is ESPEE PHARMA CANADA INC. with import value of $4.8K USD across 2 shipments. India imported Cyclophosphamide worth $11.9K USD from CANADA in total across 5 shipments.
India imported Cyclophosphamide worth $11.9K USD from CANADA across 5 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Cyclophosphamide sourced from CANADA include DR.REDDY'S LABORATORIES LTD, SHILPA MEDICARE LIMITED. The largest buyer is DR.REDDY'S LABORATORIES LTD with $11.7K in imports across 4 shipments.
The total value of Cyclophosphamide imports from CANADA to India is $11.9K USD, across 5 shipments and 4 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
5 Verified Shipments
4 suppliers, 2 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists